The evolutionary old forebrain as site of action to develop new psychotropic drugs
- PMID: 30255719
- PMCID: PMC6247451
- DOI: 10.1177/0269881118798617
The evolutionary old forebrain as site of action to develop new psychotropic drugs
Abstract
Background: Previously, the authors have developed a model of how reward-seeking and distress- avoiding behaviour is regulated by the human brain. The forebrain's evolution in vertebrates was taken as a starting point.
Aims: The authors want to inspire colleagues to study in particular the pharmacological effects on the described ancient forebrain structures in order to modify specific symptoms of mental disorders.
Methods: Compilation of data and ideas of previous articles, with examples to illustrate.
Results: A primary (lamprey-like), secondary (frog-like) and tertiary (mammal-like) forebrain can be distinguished, organized according to a Russian doll model. The first constituent is primarily involved in producing the emotional response, while the last is principally concerned with constructing conscious cognitive behaviour (including verbal and written communication). Mental disorders comprise (partly related and partly unrelated) biological and rational phenomena. The secondary system regulates the intensity of reward-seeking and distress-avoiding behaviour. An essential component of the primary forebrain evaluates the results of behavioural actions: the lateral habenula-projecting pallidum. These neurons regulate the activity of ascending dopaminergic pathways. The authors suggest that these habenula-projecting pallidum neurons are targeted by subanaesthetic dosages of ketamine. The medial habenula is enriched with nicotinergic acetylcholine receptors and regulates the activity of ascending adrenergic and serotonergic neurons. This may link varenicline-induced hostility to selective serotonin reuptake inhibitor-induced aggression.
Conclusions: Studying the effects of new compounds on the primary and secondary brains in lampreys and frogs may yield interesting new treatments of mental disorders.
Keywords: Amygdala; GPh; habenula; ketamine; varenicline.
Conflict of interest statement
Figures



References
-
- Ahmed AI, Ali AN, Kramers C, et al. (2013) Neuropsychiatric adverse events of varenicline: A systematic review of published reports. J Clin Psychopharmacol 33: 55–62. - PubMed
-
- Aizawa H, Kobayashi M, Tanaka S, et al. (2012) Molecular characterization of the subnuclei in rat habenula. J Comp Neurol 520: 4051–4066. - PubMed
-
- Aleman A, Kahn RS. (2005) Strange feelings: Do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol 77: 283–298. - PubMed
-
- Alexander GE, DeLong MR, Strick PL. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357–381. - PubMed
-
- Aloyo VJ, Berg KA, Spampinato U, et al. (2009) Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther 121: 160–173. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical